Progress in Understanding of Hairy Cell Leukemia and Hairy Cell Leukemia-Like Disorders

Nahla AM Hamed
Additional contact information
Nahla AM Hamed: Faculty of Medicine, Alexandria University, Egypt

Cancer Therapy & Oncology International Journal, 2018, vol. 12, issue 4, 64-67

Abstract: HCL is a well-recognized clinicopathological entity. BRAF-V600E mutation is present in many patients with cHCL and is absent in vHCL. Despite the remarkable progress that has been made with purine nucleoside analogs as the initial treatment of HCL patients, yet relapse and eventual development of refractory disease occurs. An appropriate approach to retreatment represents continuing areas for research.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555844.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555844.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:12:y:2018:i:4:p:64-67

DOI: 10.19080/CTOIJ.2018.12.555844

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().